Cardarine vs. Stenabolic: Mechanism of Action and Side Effects Compared
Cardarine and stenabolic are often grouped with SARMs in the supplement underground, but neither is a SARM and neither is an approved medicine. Both are research chemicals with serious safety questions. Our editorial team compares how they work and, most importantly, the documented risks that make them dangerous choices.
What these compounds actually are
Cardarine, code GW501516, is a PPAR-delta agonist. Stenabolic, code SR9009, is a compound that targets proteins called REV-ERBs. Neither binds the androgen receptor, so labeling them as SARMs, as the market often does, is simply incorrect.
Both were created as laboratory tools and drug candidates to study metabolism and endurance at the cellular level. Their appeal in fitness circles comes from animal studies suggesting effects on fat metabolism and exercise capacity.
Critically, neither compound has ever been approved as a medicine anywhere in the world. Both remain investigational or purely experimental substances, and one of them, cardarine, has a particularly troubling development history.
Understanding them requires separating the intriguing laboratory science from the reality that these are unapproved chemicals of unknown human safety, sold outside any legitimate framework.
How cardarine works
Cardarine activates PPAR-delta, a nuclear receptor that regulates how cells use fat for fuel. In animal studies, activating this pathway shifted metabolism toward burning fat and appeared to improve running endurance in mice, which is the basis for its reputation.
It was originally developed in the 1990s as a potential treatment for conditions such as abnormal cholesterol and metabolic disease. The science was genuinely interesting, and early metabolic data looked promising on paper.
However, development was halted, and the reason is the single most important fact about cardarine. Long-term animal toxicology studies found that it caused cancer in multiple organs in both rats and mice at a range of doses.
That finding ended its development as a drug. A compound that reliably induces tumors in long-term animal studies is not a borderline case; it is a clear signal that led the developer to abandon it entirely.
How stenabolic works
Stenabolic targets REV-ERB proteins, which are part of the body's circadian clock and also influence metabolism. In animal studies, activating this system altered fat and glucose handling and appeared to affect endurance and body composition.
The circadian angle is scientifically fascinating because it links the body clock to metabolism, an active area of research. In mice, SR9009 produced metabolic effects that drew attention from both scientists and the supplement market.
But stenabolic has a major practical problem rarely mentioned in marketing: it has very poor oral bioavailability. In other words, when swallowed, little of it is thought to reach the bloodstream intact, which casts doubt on whether oral products could even replicate the injected animal data.
Like cardarine, SR9009 has no approved medical use and essentially no human safety data. Its effects and risks in people are unknown, and the experimental nature of the compound cannot be overstated.
| Feature | Cardarine (GW501516) | Stenabolic (SR9009) |
|---|---|---|
| Target | PPAR-delta | REV-ERB (circadian) |
| Is it a SARM? | No | No |
| Oral bioavailability | Yes | Poor |
| Key safety signal | Cancer in animal studies | Largely unstudied in humans |
| Approved medical use | None | None |
The safety picture
For cardarine, the overriding concern is carcinogenicity. The long-term rodent studies that showed tumors across multiple tissues are the reason regulators and the original developer treat it as unsafe. This is not a theoretical worry but a documented experimental result.
No one can say what dose or duration would be safe in humans, because the compound was never advanced to establish that, precisely because of the cancer findings. Using it is, in effect, taking a substance known to cause cancer in animals with no human safety data to counter that.
For stenabolic, the problem is different but also serious: an almost total absence of human data. Its long-term effects, interactions and risks are simply unknown, and its poor oral absorption means products may not even work as claimed while still exposing users to an untested chemical.
- Cardarine: documented cancer signal in long-term animal studies.
- Stenabolic: essentially no human safety data; poor oral absorption.
- Both: unknown purity and contents when sold on the gray market.
- Both: unknown interactions with medications and other substances.
The honest conclusion is that neither compound has a safety profile that could justify non-medical use, and cardarine's cancer signal makes it especially alarming.
Legal and anti-doping status
In the United States, neither cardarine nor stenabolic is an approved drug or a legal dietary supplement ingredient. The FDA has warned against body-building products containing unapproved research chemicals of this kind.
Both are prohibited at all times by the World Anti-Doping Agency. Cardarine is specifically named, and WADA took the unusual step of issuing a public health warning about it because of its cancer risk, a rare move that underscores how seriously it is viewed.
Products sold as these compounds are frequently mislabeled or contaminated, as independent testing of the research-chemical market has repeatedly shown. A buyer has no reliable assurance of what a given product contains.
For any tested athlete, these substances guarantee a doping violation if detected, and for anyone they carry legal uncertainty and real health risk with no legitimate supply.
Conclusions of the editorial team
Cardarine and stenabolic are experimental compounds misleadingly marketed alongside SARMs. They act on entirely different pathways and share only their unapproved status and serious safety questions.
Cardarine stands out for the worst possible reason: long-term animal studies showing cancer, which ended its development and prompted an anti-doping health warning. Stenabolic is defined by an almost complete lack of human data and poor oral absorption.
Neither has a risk-benefit profile that supports non-medical use, and cardarine in particular should be regarded as dangerous.
Readers may also want our articles on why research chemicals are not supplements, on contamination in the SARM market, and on evidence-based ways to improve endurance.
References
- Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014;15(4):493–503.
- Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134(3):405–415.
- Solt LA, Wang Y, Banerjee S, et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012;485(7396):62–68.
- Geldof L, Deventer K, Roels K, et al. In vitro metabolic studies of REV-ERB agonists SR9009 and SR9011. Int J Mol Sci. 2016;17(10):1676.
- World Anti-Doping Agency. Warning on GW501516 (GW1516): a dangerous substance. WADA media statement.
- Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical composition and labeling of substances marketed as selective androgen receptor modulators. JAMA. 2017;318(20):2004–2010.
- https://farmaciadeportivaes.com/
